sur CureVac (NASDAQ:CVAC)
CureVac Announces Results of Extraordinary General Meeting
CureVac, a prominent biotech company, reported the outcomes of its Extraordinary General Meeting (EGM) held on November 25, 2025. Shareholders approved all proposals connected to BioNTech SE's public exchange offer for outstanding CureVac shares. The offer received an approval rate exceeding 99.16% of votes cast.
The exchange offer will conclude at 9:00 am ET on December 3, 2025, with shareholders encouraged to submit shares by 6:00 pm ET on December 2, 2025, due to operational timelines.
Key agenda approvals included a legal merger with CureVac Merger B.V., releasing directors from liability, and appointing new directors. Notably, the voting favoured the merger and appointments with a high percentage of affirmative votes.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CureVac